Intrinsic Value of S&P & Nasdaq Contact Us

Verona Pharma plc VRNA NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • GB • USD

SharesGrow Score
33/100
0/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$107.00
+0.1%

Financial Health Score — VRNA

Verona Pharma plc (VRNA) has an overall financial health rating of C- with a composite score of 0 out of 5.

This suggests the company faces some financial challenges worth monitoring. Rating as of 2025-10-06.

C-
Overall Rating
2025-10-06

Rating History

Date Rating DCF ROE ROA D/E P/E P/B
2025-10-06 C- -/5 -/5 -/5 -/5 -/5 -/5
2025-10-03 C- -/5 -/5 -/5 -/5 -/5 -/5
2025-10-02 C- -/5 -/5 -/5 -/5 -/5 -/5
2025-10-01 C- -/5 -/5 -/5 -/5 -/5 -/5
2025-09-30 C- -/5 -/5 -/5 -/5 -/5 -/5
2025-09-29 C- -/5 -/5 -/5 -/5 -/5 -/5
2025-09-26 C- -/5 -/5 -/5 -/5 -/5 -/5
2025-09-25 C- -/5 -/5 -/5 -/5 -/5 -/5
2025-09-24 C- -/5 -/5 -/5 -/5 -/5 -/5
2025-09-23 C- -/5 -/5 -/5 -/5 -/5 -/5
2025-09-22 C- -/5 -/5 -/5 -/5 -/5 -/5
2025-09-19 C- -/5 -/5 -/5 -/5 -/5 -/5
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message